Study confirms effective, less toxic treatment option for adults with Burkitt lymphoma
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
May 26, 2020
0
5
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
May 26, 2020
0
5
Creating new blood vessels, a process called angiogenesis, for tumors in lymph nodes is different than for tumors in other parts of the body, such as the colon or lung, a team from the Max Delbrueck Center for Molecular Medicine ...
Apr 7, 2020
0
32
(HealthDay)—The combination of low muscle mass (LMM) and low muscle density (LMD) is associated with shorter survival in patients with diffuse large B-cell lymphoma (DLBCL), according to a study published online March 13 ...
Mar 19, 2020
0
2
A new study in JNCI Cancer Spectrum finds that exposure to radiation from CT scans is associated with higher risks of developing thyroid cancer and leukemia.
Nov 19, 2019
1
4
Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not treated. Treatment for pemphigus, ...
Nov 12, 2019
0
1
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug ...
Jun 3, 2019
0
11
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists ...
Dec 2, 2018
0
3
An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma. Lymphoma ...
Dec 11, 2017
0
2
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...
Dec 10, 2017
0
0